EA201171463A1 - АНТИТЕЛА ПРОТИВ EpCAM - Google Patents

АНТИТЕЛА ПРОТИВ EpCAM

Info

Publication number
EA201171463A1
EA201171463A1 EA201171463A EA201171463A EA201171463A1 EA 201171463 A1 EA201171463 A1 EA 201171463A1 EA 201171463 A EA201171463 A EA 201171463A EA 201171463 A EA201171463 A EA 201171463A EA 201171463 A1 EA201171463 A1 EA 201171463A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
epcam
bind
cancer
treatment
Prior art date
Application number
EA201171463A
Other languages
English (en)
Inventor
Лавиния Диана Сикортас Гуннарссон
Дидрик Пеус
Дженни Маргарета Карлссон
Ремко Альберт Грип
Сергей Михайлович Киприянов
Original Assignee
Аффитек Рисеч Ас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аффитек Рисеч Ас filed Critical Аффитек Рисеч Ас
Publication of EA201171463A1 publication Critical patent/EA201171463A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Приведено описание антител, которые связываются с адгезивной молекулой эпителиальных клеток (ЕрСАМ) и демонстрируют определенное преимущество перед известными антителами, связывающимися с EpCAM, например антитела по изобретению демонстрируют высокую аффинность, хорошие профили перекрестной реактивности и превосходную активность АЗКЦ и КЗЦ. Приведено описание антител, содержащих специфичные CDR тяжелой и легкой цепей. Таким образом, настоящее изобретение относится к таким антителам и всем их применениям, в частности, для лечения онкологического заболевания. Следовательно, настоящее изобретение направлено на создание новых композиций на основе антител, способов и комбинированных протоколов для лечения онкологического заболевания. Также описаны полезные композиции иммуноконъюгатов и способов, в которых применяются новые антитела против EpCAM.
EA201171463A 2009-06-09 2010-06-09 АНТИТЕЛА ПРОТИВ EpCAM EA201171463A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18538709P 2009-06-09 2009-06-09
GBGB0909904.5A GB0909904D0 (en) 2009-06-09 2009-06-09 Product
PCT/GB2010/050969 WO2010142990A1 (en) 2009-06-09 2010-06-09 ANTI-EpCAM ANTIBODIES

Publications (1)

Publication Number Publication Date
EA201171463A1 true EA201171463A1 (ru) 2012-07-30

Family

ID=40937119

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171463A EA201171463A1 (ru) 2009-06-09 2010-06-09 АНТИТЕЛА ПРОТИВ EpCAM

Country Status (8)

Country Link
US (1) US8637017B2 (ru)
EP (1) EP2440580A1 (ru)
JP (1) JP2012529281A (ru)
CN (1) CN102549017A (ru)
BR (1) BRPI1011005A2 (ru)
EA (1) EA201171463A1 (ru)
GB (1) GB0909904D0 (ru)
WO (1) WO2010142990A1 (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196366A1 (en) 2003-04-30 2007-08-23 Uwe Zangemeister-Wittke Methods for treating cancer using an immunotoxin
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2007312367B2 (en) 2006-10-12 2012-09-06 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-EREG antibody
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
EP2686020B1 (en) 2011-03-17 2017-02-22 The University of Birmingham Re-directed immunotherapy
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
WO2013131001A1 (en) * 2012-03-02 2013-09-06 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
PL2897978T3 (pl) * 2012-09-19 2017-08-31 Abbvie Biotherapeutics Inc. Sposoby identyfikacji przeciwciał o obniżonej immunogenności
CN103387988B (zh) * 2012-09-24 2016-01-06 厦门大学 上皮细胞粘附分子的核酸适体EpCAM Ccut及其制备方法
US20140248292A1 (en) * 2013-03-04 2014-09-04 Oslo Universitetssykehus Hf Compositions and methods for treating cancer
EA201591652A1 (ru) * 2013-03-06 2016-02-29 Мерримак Фармасьютикалз, Инк. ТАНДЕМНЫЕ БИСПЕЦИФИЧЕСКИЕ Fc-АНТИТЕЛА ПРОТИВ c-MET
KR20160006697A (ko) * 2013-04-12 2016-01-19 비벤티아 바이오 인코포레이티드 간세포 암종을 검출 및 치료하기 위한 조성물 및 방법
CN103275226B (zh) * 2013-06-09 2017-08-29 中国科学技术大学 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用
RU2016101716A (ru) * 2013-06-24 2017-07-27 Чугаи Сейяку Кабусики Кайся Терапевтический агент, содержащий гуманизированное антиэпирегулиновое антитело в качестве действующего ингредиента для немелкоклеточной карциномы легкого, за исключением аденокарциномы
US9822182B2 (en) 2013-10-02 2017-11-21 Viventia Bio Inc. Anti-EPCAM antibodies and methods of use
CA2979400A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Dosing strategies for targeting epcam positive bladder cancer
CN108513547A (zh) 2015-03-12 2018-09-07 维文蒂亚生物公司 用于epcam阳性膀胱癌的治疗方法
JP6901400B2 (ja) * 2015-04-03 2021-07-14 ゾーマ テクノロジー リミテッド ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法
EP3328897A1 (en) 2015-07-31 2018-06-06 Sutro Biopharma, Inc. ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EPCAM ANTIBODIES
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
EP3490589A1 (en) 2016-07-26 2019-06-05 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
CN107814846A (zh) * 2016-11-14 2018-03-20 杭州华得森生物技术有限公司 针对EpCAM和Cytokeratin5的特异性抗体及其制备方法
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
BR112020016190A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Domínios variáveis de anticorpos direcionando o receptor nkg2d
CN108484771A (zh) * 2018-04-24 2018-09-04 南京市妇幼保健院 EpCAM单域抗体G7
JPWO2019244973A1 (ja) 2018-06-20 2021-07-08 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
TW202029980A (zh) * 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
WO2020131697A2 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
CN113597432B (zh) * 2019-04-22 2023-05-02 江苏恒瑞医药股份有限公司 抗EpCAM抗体及其应用
CN110950959B (zh) * 2020-02-25 2020-07-03 和铂医药(上海)有限责任公司 靶向EpCAM的抗体及其制备和应用
CN111333730B (zh) * 2020-03-11 2022-04-08 南京融捷康生物科技有限公司 可特异性结合EpCAM的单域抗体及其应用
US11919944B2 (en) 2020-05-11 2024-03-05 Augmenta Biosciences, Inc. Antibodies for SARS-CoV-2 and uses thereof
CN112359052B (zh) * 2020-08-20 2023-01-03 山东兴瑞生物科技有限公司 抗EpCAM嵌合抗原受体的编码基因、制备方法、具有该基因的质粒、免疫细胞及其应用
TW202241967A (zh) * 2021-01-11 2022-11-01 美商索特里亞生物治療藥物公司 基於茚地那韋的化學二聚化ｔ細胞銜接器組成物
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
CN113563474B (zh) * 2021-06-11 2023-05-02 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） EpCAM-CD16-NKG2D三特异性抗体及其应用
WO2024082269A1 (zh) * 2022-10-21 2024-04-25 武汉友芝友生物制药股份有限公司 双特异性抗体在免疫细胞治疗方面的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
CA2452130A1 (en) 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
PL193780B1 (pl) 1997-04-14 2007-03-30 Micromet Ag Sposób wytwarzania receptora przeciw ludzkim antygenom, ludzkie przeciwciało i środek farmaceutyczny
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
DE60038132T2 (de) 1999-12-27 2009-04-02 Crucell Holland B.V. Antikörper gegen Ep-Cam
CA2446087C (en) * 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
DE10143106C1 (de) 2001-09-03 2002-10-10 Artus Ges Fuer Molekularbiolog Vermehrung von Ribonukleinsäuren
CN1812999A (zh) * 2003-05-31 2006-08-02 麦克罗梅特股份公司 包含EpCAM特异构建体的药物组合物
AU2006301492B2 (en) * 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
EA023679B1 (ru) * 2007-04-04 2016-06-30 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. АНТИ-EpCAM АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
US8802442B2 (en) 2011-11-30 2014-08-12 Eric B. Wheeldon Apparatus and method for the remote sensing of blood in human feces and urine

Also Published As

Publication number Publication date
GB0909904D0 (en) 2009-07-22
JP2012529281A (ja) 2012-11-22
EP2440580A1 (en) 2012-04-18
CN102549017A (zh) 2012-07-04
US20100310463A1 (en) 2010-12-09
US8637017B2 (en) 2014-01-28
BRPI1011005A2 (pt) 2018-03-06
WO2010142990A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
EA201171463A1 (ru) АНТИТЕЛА ПРОТИВ EpCAM
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
BR112017027877A2 (pt) anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico isolado, vetor, célula hospedeira, método para preparar o anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, cepa de célula hibridoma lt005, conjugado, conjugado de anticorpo bifuncional, anticorpo multiespecífico, composição farmacêutica e uso do anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo
EA201690310A1 (ru) Антитела, связывающие cd27 человека, и их применение
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
WO2013054331A8 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
AU2017297138A8 (en) Anti-PD-1 antibodies, method for producing same and method for using same
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40
NZ737726A (en) Multispecific antigen-binding molecules and uses thereof
NZ623607A (en) Anti-gcc antibody molecules and related compositions and methods
RU2011145038A (ru) Несущие аматоксины мишень-связывающие молекулы для лечения рака
EP3461847A8 (en) Humanized antibodies to liv-1 and use of same to treat cancer
UA95068C2 (ru) Антиген-связующая молекула, которая связывает egfr, вектор, который ее кодирует, и их применение
CL2016002689A1 (es) Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
WO2013173496A3 (en) Cd33 antibodies and use of same to treat cancer
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
MX2021000397A (es) Moleculas de union a mesotelina y cd137.
MX2021000399A (es) Moleculas de anticuerpo que se unen a cd137 y ox40.
TN2014000107A1 (en) Anti-aplhabetatcr antibody
MX2011009220A (es) Anticuerpos completamente humanos especificos para la molecula de adhesion celular 1.
EA202091747A1 (ru) Составы антитела b7-h4